Keywords
Bisphosphonate-associated osteonecrosis of the jaw
Risk factors
Jaw
How to Cite
Abstract
Aim: This study aimed to identify risk factors for medicationrelated osteonecrosis of the jaw (MRONJ) by carrying out clinical and radiographic evaluations of patients with osteopenia and osteoporosis using bisphosphonates (BFs). Methods: After approval by the CCS/UFES Ethics Committee (registration number 2,738,749), consultations were undertaken, and data were collected from medical records in cooperation with sectors from UFES and the University hospital. A total of 50 patients, 29 with osteoporosis and 21 with osteopenia were selected. Patients underwent a clinical and a panoramic dental x-ray examination to assess risk factors associated with oral health and dental interventions. Results: All patients had at least one local risk factor, the most frequent being tooth extraction (100%) and periodontal disease (50%) which, if associated with the use of BFs, could lead to MRONJ. Among the systemic risk factors, the most common were diabetes and corticosteroid therapy. The most used BF was alendronate, administered orally. Conclusion: The dental surgeon should evaluate all patients with osteopenia and osteoporosis using BFs to determine whether there are other risks. Whether there may be other potential risks, acknowledging upon key risks factors surrounding MRONJ are critical for early diagnosis and successful dental treatment.
References
Takahashi TA, Johnson KM. Menopause. Med Clin North Am. 2015 May;99(3):521-34. doi: 10.1016/j.mcna.2015.01.006.
Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med. 2006 Apr;119(4 Suppl 1):S3-S11. doi: 10.1016/j.amjmed.2005.12.017.
Govaerts D, Piccart F, Ockerman A, Coropciuc R, Politis C, Jacobs R. Adjuvant therapies for MRONJ: A systematic review. Bone. 2020 Dec;141:115676. doi: 10.1016/j.bone.2020.115676.
Ruggiero SL, Woo SB. Biophosphonate-related osteonecrosis of the jaws. Dent Clin North Am. 2008 Jan;52(1):111-28, ix. doi: 10.1016/j.cden.2007.09.002.
Ficarra G, Beninati F. Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects. Head Neck Pathol. 2007 Dec;1(2):132-40. doi: 10.1007/s12105-007-0033-2.
Pichardo SEC, van der Hee JG, Fiocco M, Appelman-Dijkstra NM, van Merkesteyn JPR. Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws (MRONJ). Br J Oral Maxillofac Surg. 2020 Sep;58(7):771-6. doi: 10.1016/j.bjoms.2020.03.022.
Krois J, Ekert T, Meinhold L, Golla T, Kharbot B, Wittemeier A, et al. Deep learning for the radiographic detection of periodontal bone loss. Sci Rep. 2019 Jun;9(1):8495. doi: 10.1038/s41598-019-44839-3.
Machado V, Proença L, Morgado M, Mendes JJ, Botelho J. Accuracy of panoramic radiograph for diagnosing periodontitis comparing to clinical examination. J Clin Med. 2020 Jul;9(7):2313. doi: 10.3390/jcm9072313.
Bell BM, Bell RE. Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg. 2008 May;66(5):1022-4. doi: 10.1016/j.joms.2007.12.040.
Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab. 2007 Mar;92(3):1172-5. doi: 10.1210/jc.2006-2036. Epub 2006 Dec 19.
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004 May;62(5):527-34. doi: 10.1016/j.joms.2004.02.004.
Compston J. HIV infection and osteoporosis. Bonekey Rep. 2015 Feb;4:636. doi: 10.1038/bonekey.2015.3.
Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007 Mar;65(3):369-76. doi: 10.1016/j.joms.2006.11.003.
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7. doi: 10.1016/s0278-2391(03)00720-1.
Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. 2003 Nov;21(22):4253-4. doi: 10.1200/JCO.2003.99.132.
Adami G, Fassio A, Rossini M, Caimmi C, Giollo A, Orsolini G, et al. Osteoporosis in rheumatic diseases. Int J Mol Sci. 2019 Nov;20(23):5867. doi: 10.3390/ijms20235867.
Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007 Aug;29(8):1548-58. doi: 10.1016/j.clinthera.2007.08.008.
Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc. 2005 Dec;136(12):1675-81. doi: 10.14219/jada.archive.2005.0110.
Ananchenko G, Novakovic J, Tikhomirova A. Alendronate sodium. Profiles Drug Subst Excip Relat Methodol. 2013;38:1-33. doi: 10.1016/B978-0-12-407691-4.00001-0.
Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. doi: 10.1016/j.bone.2005.05.003. Epub 2005 Jul 20.
White NJ, Perry CM. Risedronate once a week. Treat Endocrinol. 2003;2(6):415-20; discussion 421. doi: 10.2165/00024677-200302060-00005.
Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T, Urade M. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab. 2010 Jul;28(4):365-83. doi: 10.1007/s00774-010-0162-7.
Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010 Feb;68(2):243-53. doi: 10.1016/j.joms.2009.03.050. Epub 2009 Sep 24.
Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Feb;127(2):117-35. doi: 10.1016/j.oooo.2018.09.008. Epub 2018 Oct 9.
Şahin O, Odabaşı O, Aliyev T, Tatar B. Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation. J Korean Assoc Oral Maxillofac Surg. 2019 Apr;45(2):108-15. doi: 10.5125/jkaoms.2019.45.2.108.
Koka S, Clarke BL, Amin S, Gertz M, Ruggiero SL. Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient. Int J Prosthodont. 2007 Mar-Apr;20(2):115-22.
Wang CJ, McCauley LK. Osteoporosis and Periodontitis. Curr Osteoporos Rep. 2016 Dec;14(6):284-91. doi: 10.1007/s11914-016-0330-3.
Koka S, Babu NM, Norell A. Survival of dental implants in post-menopausal bisphosphonate users. J Prosthodont Res. 2010 Jul;54(3):108-11. doi: 10.1016/j.jpor.2010.04.002.
Liddelow G, Klineberg I. Patient-related risk factors for implant therapy. A critique of pertinent literature. Aust Dent J. 2011 Dec;56(4):417-26; quiz 441. doi: 10.1111/j.1834-7819.2011.01367.x.
Donos N, Calciolari E. Dental implants in patients affected by systemic diseases. Br Dent J. 2014 Oct;217(8):425-30. doi: 10.1038/sj.bdj.2014.911.
Do TA, Le HS, Shen YW, Huang HL, Fuh LJ. Risk factors related to late failure of dental implant-a systematic review of recent studies. Int J Environ Res Public Health. 2020 Jun;17(11):3931. doi: 10.3390/ijerph17113931.
Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi M, et al. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos Int. 2023 Jun;34(6):1141-4. doi: 10.1007/s00198-023-06745-3. Erratum for: Osteoporos Int. 2017 Aug;28(8):2465-2473. doi: 10.1007/s00198-017-4063-7.
Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007 Mar;65(3):415-23. doi: 10.1016/j.joms.2006.10.061.
Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011 Nov;142(11):1243-51. doi: 10.14219/jada.archive.2011.0108.
Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L, et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int. 2018 Sep;2018:2684924. doi: 10.1155/2018/2684924.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Jocarla Campos Serafim, Gustavo Azevedo Pitol, Ester Victorino Coser, Ben-Hur Albergaria, Stefania Carvalho Kano, Tânia Regina Grão Velloso
Downloads
